Research Analysts Offer Predictions for ACRV FY2024 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Acrivon Therapeutics in a research report issued to clients and investors on Monday, February 3rd. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings of ($2.42) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.51) per share. Cantor Fitzgerald also issued estimates for Acrivon Therapeutics’ FY2025 earnings at ($2.55) EPS.

Several other equities research analysts have also recently issued reports on ACRV. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. BMO Capital Markets cut their price objective on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Finally, KeyCorp assumed coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Acrivon Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.67.

Acrivon Therapeutics Stock Performance

ACRV stock opened at $6.97 on Wednesday. Acrivon Therapeutics has a one year low of $3.19 and a one year high of $11.90. The firm has a market cap of $217.02 million, a PE ratio of -2.58 and a beta of 0.77. The firm’s 50 day moving average price is $6.27 and its 200-day moving average price is $7.31.

Institutional Trading of Acrivon Therapeutics

A number of large investors have recently modified their holdings of the stock. Exome Asset Management LLC acquired a new position in Acrivon Therapeutics in the third quarter valued at approximately $817,000. State Street Corp boosted its position in shares of Acrivon Therapeutics by 26.4% in the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after purchasing an additional 47,233 shares during the period. JPMorgan Chase & Co. grew its stake in Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after buying an additional 28,748 shares during the last quarter. Barclays PLC increased its position in Acrivon Therapeutics by 51.2% during the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after buying an additional 11,273 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Acrivon Therapeutics during the second quarter worth approximately $58,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.